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S12 Concurrent Session 9 – HBV: Treatment Options and Strategies
Interferon-based anti-viral drugs have dual actions of viral sup-
pression and immune modulation; thereby have a higher chance
of eradicating HBV and the infected hepatocytes. Pegylated in-
terferon alfa-2a therapy for one year resulted in incremental
HBsAg loss up to 9% and 11% by year 3 and year 4 respectively
after completion of therapy. Higher baseline ALT level, female
patients, HBV genotype A have been reported to favour response.
The viral kinetics during therapy, the proﬁle of decline in serum
HBV DNA, quantitative HBeAg and HBsAg levels, are useful in
identifying the patients likely to achieve sustained virologic re-
sponse, which is relatively low at 30-40%. The deﬁned duration of
therapy make pegylated interferon therapy a choice for treating
younger patients planning family in the future. These patients
need careful counselling and should be warned about immediate
and longer term known side-effects. They should be followed and
monitored regularly at 4 to 8 weekly intervals. Long term follow-
up data showed a signiﬁcant reduction in serious complications
of CHB including reduced incident of hepatocellular carcinoma
among those responded to standard interferon therapy. Similar,
if not better, results are anticipated after therapy with peylated
interferon.
Oral nuceos(t)ide analogues (NAs) act directly and purely by
suppressing the HBV DNA polymerase, though there may be some
secondary stimulus effect on the host immune system when viral
load is suppressed rapidly. NAs have the distinct advantage of
low primary non-responder rate. Lamivudine and adefovir have
been available for many years. Clinical experience over the years
showed high rate of emergence of resistant mutants and moder-
ate antiviral effect. Patients on these NAs require more frequent
monitor and add-on therapy should resistance developed. Tel-
bivudine, by comparison, is more potent and has lower resistant
proﬁle. The choice is easier when entecavir and tenofovir be-
come available in the market. The consistent and rapid viral
suppression, coupled with a much, much lower incident of drug
resistant make long term therapy possible. Side-effects are few.
The efﬁcacy is not age, gender, ALT, and HBV genotype dependent
and can be used in patients with cirrhosis and decompensated
disease.
Pivotal clinical trials usually recruit patients of certain age group
and speciﬁc disease characteristics. The role and safety of the
newer NAs in the children and young adults with CHB, patients
in immune tolerant phase, and in pregnant women, are still
not clear. The role of NA as a prophylactic therapy to prevent
relapse or exacerbation of CHB during chemotherapy or steroid
treatment has been demonstrated. Another milestone role of
NA is the suppression of HBV in liver and other organ/tissue
transplantations. The success of transplantation for CHB patients
cannot be realized without potent suppression of HBV to stamp
out HBV recurrence in the immune compromised state.
Current available therapy has created a signiﬁcant impact in HBV
infection and has improved the prognosis of CHB patients. Much
more advances are needed to control this disease, to inhibit more
profoundly, to eradicate more rapidly. We are at a turning point
and should witness a downward trend in mortality and morbidity
of cirrhosis and HCC, the real goal of HBV therapy.
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China is a highly endemic area for hepatitis B virus (HBV) in-
fection with the biggest HbsAg carrier population in the world.
The management of chronic hepatitis B (CHB) has improved
dramatically over the last decade with the development of new
antiviral drugs. In addition to the standard interferon (IFN)-
alpha therapy, 4 nucleotide/nucleoside analogues (lamivudine,
adefovir dipivoxil, entecavir and telbivudine) and 2 pegylated
interferon (pegasys and pegintron) have been approved for the
treatment of chronic hepatitis B. Long-term therapy with nucle-
oside/nucleotide analogues, both in HBeAg+ and HBeAg- CHB,
has most favourable effects on patient outcome, provided that
virological and biochemical remission is maintained without de-
velopment of viral resistance. However, drug resistance become
increasingly challenging to clinical management of patients with
CHB. Here I would like to focus my presentation on 2 recent
studies related with HBV resistance in China.
The ﬁrst study is an open-label, randomized, controlled study to
compare the efﬁcacy and safety of peginterferon alfa-2a versus
adefovir dipivoxil (ADV) in treating lamivudine resistant HBeAg
positive CHB. Up to 70% of patients treated with lamivudine
develop drug resistance after 5 years. Rescue therapies with
oral antivirals are limited due to the cross-resistance proﬁles of
nucleos(t)ide analogs. A ﬁnite course of peginterferon alfa-2a
can offer the possibility of achieving sustained post-treatment
response in these difﬁcult-to-treat patients. In order to deter-
mine if on-treatment quantiﬁcation of HBsAg can help identify
the patients with lamivudine-resistant HBV most likely to achieve
sustained post-treatment response to peginterferon alfa-2a,
quantitative HBsAg levels were measured retrospectively at base-
line and at week 24 and 48 using the Architect QT assay (Abbott
Diagnostics) in available sera of 155 patients who received pegin-
terferon alfa-2a 180 μg qw for 48 weeks or 80 patients with ade-
fovir dipivoxil (ADV) 10mg daily for 72 weeks. All patients were
HBeAg-positive with documented resistance to lamivudine (YMDD
mutation). All patients continued LAM treatment 100mg daily
for the ﬁrst 12 weeks. The primary efﬁcacy endpoint was HBeAg
seroconversion at Week 72 (6 months post-treatment in pegin-
terferon alfa-2a arm or at the end of treatment in adefovir arm).
HBeAg seroconversion at Week 72 was signiﬁcantly higher in the
peginterferon alfa-2a arm (11.6% vs 3.8%, p=0.045). Three of
the 18 patients treated with peginterferon alfa-2a who achieved
HBeAg seroconversion also achieved HBsAg seroconversion. No
ADV-treated patient cleared HBsAg. HBsAg decline from base-
line was more pronounced in the peginterferon alfa-2a-treated
patients. At week 24, 31% of the peginterferon alfa-2a-treated
patients with available data had HBsAg levels <1500 IU/ml,
compared with 14% of those treated with ADV. The rate of HBeAg
seroconversion 6 months post-treatment was twice as high in
peginterferon alfa-2a-treated patients with HBsAg <1500 IU/ml
at W24. There was no association between HBsAg level at week
24 and response to ADV.
Our data show that peginterferon alfa-2a represents a vi-
able treatment strategy for difﬁcult-to-treat patients who bear
lamivudine-resistant YMDD mutations and was superior to ADV
in achieving HBeAg seroconversion. Quantiﬁcation of HBsAg level
at week 24 may help identify those most likely to beneﬁt from
peginterferon alfa-2a.
The second study is about adefovir dipivoxil (ADV) resistance at
5 years in Chinese HBeAg+ve chronic hepatitis B. Long term ADV
provides clinical and histological improvement in CHB, but as
with all oral therapies may lead to emergence of ADV resistance-
associated mutations. Long term ADV resistance data are best
documented in a HBeAg negative population. At 5 years the
cumulative probability of resistant mutation with virological re-
sistance was 29%. We report ADV resistance data from a cohort
of Chinese HBeAg positive subjects treated for 5 years.
Four hundred and eighty HBeAg positive CHB subjects were ran-
domized in an initial 52 weeks controlled ADV study (with a
12 weeks placebo period in two thirds of patients) and then
offered open label ADV treatment for a further 208 weeks. Four
hundred and eighty subjects were enrolled in the ﬁrst year study,
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a total of 474, 456, 443, 421, and 370 subjects completed the
1st, 2nd, 3rd, 4th, and 5th yr study, respectively. At the end
of each year, samples were analyzed from those subjects with
protocol-deﬁned HBV DNA breakthrough (increase ≥ 1.0 log10
copy/ml from the treatment nadir) for the rtN236T or rtA181V
ADV mutations associated with in vitro ADV resistance. ADV was
associated with a low rate of resistance, cumulative rate of 0%
after 1 year,1.3% after 2 years, 5.4% after 3 years and 10.4% after
4 years, 14.6% after 5 years.
Our data showed that treatment with ADV in Chinese HBeAg
positive CHB subjects for up to 5 years resulted in a cumulative
rate of 14.6% (70/480) ADV resistance-associated mutations with
HBV DNA breakthrough.
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Antibacterial agents are the most common used drug in daily clin-
ical practice, in which the wide application and high requirement
for professional capability often leads irrational prescription.
The professionals are urgent need for promoting antibiotic use.
Infectious disease physicians should take the key role in the work
because:
1. Infectious doctors holding professional priority:
a. One of the responsibilities endue with infectious doctor is
therapy of infections;
b. Antibiotic is the major therapeutic measure for infectious
doctor;
c. Infectious doctors are familiar with all the basic infor-
mation related with infection and chemotherapy, such as
bacteriology, virology and antibiotics;
d. Infectious doctors are in the center for contacting pharma-
cist, microbiologist and nosocomial infection controller.
2. Infectious doctors should do following effect to conduct the
work well:
a. Afﬂuent experience in diagnosis and treatment of infec-
tious diseases;
b. Substantial basic medical knowledge, such as epidemiol-
ogy, bacteriology, pathogenesis, pathology, etc;
c. Catching up with new information concerning with their
occupation, such as bacterial resistance, new antibacterial
therapeutic strategy, etc;
d. Familiar with all the information of antibacterial agents,
such as pharmacodynamics, pharmacokinetics, dosing, side
effect, indications, etc.
3. Infectious doctors should take the role by:
a. Collaboration with their clinical co-workers in other ﬁelds;
b. Collaboration with pharmacist, microbiologist and hospital
manager;
c. Active participation for clinical consulting;
d. Personal professional improvement;
e. Holding education and training in hospital about antibac-
terial rational use;
f. Conducting clinical and basic researches.
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It is widely accepted that in community antibiotic/antifungal
resistance is related with consumption. One of the arguments
“pro” is reversibility of resistance which happens frequently in
hospital but was detected also in the community level in at least
3 countries (Denmark, Iceland and Finland).
As every rule is conﬁrmed by an exception, here are several
examples of antimicrobial resistance in regions with no or very
little antimicrobial pressure. We have observed and published
data on absence of resistance to penicillin, oxacillin and ery-
thromycin in S. pneumoniae and S. aureus in an area isolated 21
years by civil war in southern Sudan with no communication, no
health infrastructure and no antimicrobial drugs on the market
however among the same patients 80% tetracycline resistance in
viridans streptococci was observed.
We have observed 66-75% ceftazidim resistance in Enterobacter
spp. Isolated from Cambodian HIV positive children living in
rural areas where no antibiotic drugs are accessible. Last year
a report on high quinolone resistance in E. coli from indigenous
Indian population in rural Bolivia was published by Bartoloni et
al. Similar situation was observed among inhabitants of very
isolated villages from Amazon basin in Peru and Bolivia. Shahum
et al. described 8 children infected with voriconazol resistant
Candida spp. strains from rain forest rural area of Cambodia
near Viet Nam border. Those children and their parents never
received according to patient’s history and medication for years.
Other two similar observations are coming from Nepal and French
Guyana. Those at least 7 reports does no weak our conclusion
that consumption of antibiotics is a major driver of antimicrobial
resistance in the community. However ﬁndings from southern
Sudan, Cambodia, Peru and Bolivia indicate that other factors
promoting antimicrobial resistance in absence of antimicrobial
pressure should be studied as well.
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The discovery of antibiotics is one of the most signiﬁcant event
in medical history. Antibiotics have added a decade to the aver-
age life expectancy. Together with vaccination, clean water and
other public health measures, mortality from infectious diseases
was dramatically reduced. There was great optimism in the
1950s and 1960s that infectious diseases were no longer a major
challenge. Unfortunately this optimism was unfounded due to
various reasons including the emergence of antibiotic resistance.
Resistance is not new. Sir Alexander Fleming, the discoverer of
penicillin said in his Nobel Prize Address in 1945 that, “It is not
difﬁcult to make microbes resistant to penicillin in the laboratory
by exposing them to concentrations not sufﬁcient to kill them,
and the same thing has occasionally happened in the body.”
The resistome is the collection of all the antibiotic resis-
tance genes and their precursors both in pathogenic and non-
pathogenic bacteria. Studies of the soil resistome has revealed
antibiotic resistant genes to a wide variety of antibiotics in-
cluding synthetic compounds like quinolones and newer antimi-
crobials like Synercid and daptomycin despite no known prior
exposure to these antibiotics or their analogues. The develop-
ment of antimicrobial resistance had therefore been going on in
nature long before antibiotics came into medicinal use. A recent
study has also shown that bacteria can subsist on antibiotics as
their sole carbon source. The soil resistome therefore constitute
an unappreciated reservoir that can contribute to increasing
resistance in pathogenic bacteria
Antibiotic resistance is a major challenge world-wide. It occurs in
gram positive as well in gram negative organisms and in health-
care associated as well as in community acquired infections. In
the last two decades only 2 new classes of anti-bacterials (the
oxazolidinones and the lipopeptides) have been introduced for
clinical use. The situation is now so dire that some physicians
have predicted that there will not be any effective antibiotics to
treat seriously ill patients in the near future.
